Header Logo

Connection

RAJENDER APARASU to Child

Back to Details
This is a "connection" page, showing publications RAJENDER APARASU has written about Child.
RAJENDER APARASU
Connection Strength
0.558
Child
  1. Documentation of asthma control and severity in pediatrics: analysis of national office-based visits. J Asthma. 2020 02; 57(2):205-216.
    View in: PubMed
    Score: 0.038
  2. Asthma Medication Prescribing Practices in Pediatric Office Visits. Clin Pediatr (Phila). 2019 04; 58(4):395-405.
    View in: PubMed
    Score: 0.038
  3. Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. J Atten Disord. 2019 01; 23(2):163-172.
    View in: PubMed
    Score: 0.030
  4. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder. J Manag Care Spec Pharm. 2015 Jun; 21(6):486-98.
    View in: PubMed
    Score: 0.029
  5. Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid. Psychiatr Serv. 2015 Apr 01; 66(4):404-10.
    View in: PubMed
    Score: 0.029
  6. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012 Apr; 22(2):139-48.
    View in: PubMed
    Score: 0.023
  7. Prevalence and predictors of human papillomavirus vaccination in adolescent girls. J Am Pharm Assoc (2003). 2012 Jan-Feb; 52(1):52-8.
    View in: PubMed
    Score: 0.023
  8. The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv. 2011 Dec; 62(12):1450-5.
    View in: PubMed
    Score: 0.023
  9. Extent of functional impairment in children and adolescents with depression. Curr Med Res Opin. 2010 Sep; 26(9):2057-64.
    View in: PubMed
    Score: 0.021
  10. Unmet prescription medication need in U.S. children. J Am Pharm Assoc (2003). 2009 Nov-Dec; 49(6):769-76.
    View in: PubMed
    Score: 0.020
  11. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar; 6(1):78-84.
    View in: PubMed
    Score: 0.020
  12. Pharmacotherapy with atomoxetine for US children and adolescents. Ann Clin Psychiatry. 2007 Jul-Sep; 19(3):175-80.
    View in: PubMed
    Score: 0.017
  13. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin. 2007 Jan; 23(1):49-56.
    View in: PubMed
    Score: 0.016
  14. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
    View in: PubMed
    Score: 0.014
  15. Pain-related hospitalization and emergency room visit following initial analgesic prescription after outpatient surgery. Pharmacoepidemiol Drug Saf. 2024 02; 33(2):e5759.
    View in: PubMed
    Score: 0.013
  16. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.013
  17. Trends in Repeat Opioid Analgesic Prescription Utilization for Acute Pain in Children: 2013-2018. Acad Pediatr. 2024 07; 24(5):776-782.
    View in: PubMed
    Score: 0.013
  18. Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
    View in: PubMed
    Score: 0.013
  19. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.013
  20. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023 01; 359:114238.
    View in: PubMed
    Score: 0.012
  21. Association Between Initial Opioid Prescription Duration and 30-Day Risk of Receiving Repeat Opioid Among Children. Acad Pediatr. 2023 03; 23(2):416-424.
    View in: PubMed
    Score: 0.012
  22. Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
    View in: PubMed
    Score: 0.011
  23. Autonomous ambulatory care by nurse practitioners and physician assistants in office-based settings. J Allied Health. 2001; 30(3):153-9.
    View in: PubMed
    Score: 0.011
  24. Utilization of ambulatory care services caused by adverse effects of medications in the United States. Manag Care Interface. 2000 Apr; 13(4):70-5.
    View in: PubMed
    Score: 0.010
  25. Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
    View in: PubMed
    Score: 0.010
  26. Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019 06; 276:151-159.
    View in: PubMed
    Score: 0.010
  27. The association between geographic access to providers and the treatment quality of pediatric depression. J Affect Disord. 2019 06 15; 253:162-170.
    View in: PubMed
    Score: 0.010
  28. Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
    View in: PubMed
    Score: 0.009
  29. Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019 04; 15(4):395-403.
    View in: PubMed
    Score: 0.009
  30. Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. J Affect Disord. 2018 08 01; 235:155-161.
    View in: PubMed
    Score: 0.009
  31. Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
    View in: PubMed
    Score: 0.008
  32. Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatr Serv. 2017 Jul 01; 68(7):681-688.
    View in: PubMed
    Score: 0.008
  33. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. J Child Adolesc Psychopharmacol. 2014 Dec; 24(10):551-61.
    View in: PubMed
    Score: 0.007
  34. Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiol Drug Saf. 2014 Mar; 23(3):299-308.
    View in: PubMed
    Score: 0.007
  35. The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. J Affect Disord. 2013 Sep 05; 150(2):424-9.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.